Ongoing Investigation into Actinium Pharmaceuticals by Faruqi & Faruqi, LLP: Investors Beware

Ongoing Investigation into Actinium Pharmaceuticals by Faruqi & Faruqi, LLP

Faruqi & Faruqi, LLP, a highly regarded national securities law firm, is actively looking into allegations against Actinium Pharmaceuticals, Inc., a company in the biotechnology sector that is publicly traded on the NYSE under the ticker ATNM. This inquiry primarily aims to address possible claims made by investors who have incurred losses exceeding $75,000 from October 31, 2022, to August 2, 2024, as a result of misleading statements from the company.

Background of the Investigation

The firm highlights the importance of a deadline approaching on May 26, 2025, which investors should note if they wish to assume the role of lead plaintiff in an ongoing federal securities class action against Actinium. The investigation is particularly crucial for stakeholders who may feel their investment decisions were influenced by erroneous information released by the company.

The complaints allege that Actinium and its executives failed to disclose critical information regarding their product, Iomab-B, particularly concerning the regulatory compliance issues associated with the FDA’s requirements. Specifically, it is claimed that the data from the Sierra Trial, which is pivotal for the acceptance of the Iomab-B Biologics License Application (BLA), may not meet FDA guidelines. This violation of federal securities laws has raised serious concerns among investors.

The Significance of the Claims

Investors have suffered significant losses as the stock price of Actinium has been adversely affected as the negative information gradually became public. Notably, on August 5, 2024, Actinium issued a press release indicating additional trials would be needed to support the BLA filing. Following this disclosure, Actinium's stock plummeted by nearly 60%, showcasing the severe impact of potentially misleading statements.

Who Can Participate?

Anyone who experienced a significant financial loss due to these developments is encouraged to reach out to Faruqi & Faruqi, LLP. The firm also invites whistleblowers, former employees, and shareholders with potentially relevant information about Actinium’s practices to come forward, assuring full confidentiality.

Potential class members can either choose to take an active role as lead plaintiff or remain passive participants in the class action. Whether they decide to pursue lead plaintiff status or not will not affect their eligibility for any potential recovery stemming from the lawsuit.

Next Steps for Investors

Investors who believe they meet the criteria are urged to act swiftly and contact Josh Wilson, a partner at Faruqi & Faruqi, either via phone at 877-247-4292 or through the firm’s website. Understanding one’s legal rights in this matter is pivotal, especially considering the rapid changes and developments in the biotech field and the specific challenges facing Actinium.

Conclusion

The scrutiny surrounding Actinium Pharmaceuticals serves as a cautionary tale for investors in the biotech and pharmaceutical markets, particularly concerning compliance with federal regulations. As Faruqi & Faruqi, LLP continues its investigation, investors and stakeholders must stay informed and proactive in safeguarding their financial interests. Regular updates regarding the case will be shared via internet platforms such as LinkedIn, X, and Facebook, reinforcing the firm’s commitment to transparency and communication throughout this evolving situation.